Imprimis Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 10 100 - -
Cost of Revenue - - - -
Gross Profit 10 100 - -
Operating Expenses
Research and Development 1,616 1,299 112 195
Sales, General and Admin. 6,081 2,980 828 2,308
Non-Recurring Items - - - -
Other - - - -
Operating Income (7,687) (4,179) (939) (2,503)
Income From Continuing Operations
Add'l Income/Expense Items 44 (1,180) 60 27
Earnings Before Interest and Tax (7,643) (4,163) (879) (2,476)
Interest Expense - 25 75 55
Earnings Before Tax (7,643) (4,188) (954) (2,531)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (7,643) (5,384) (894) (2,505)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (7,643) (5,384) (954) (2,531)
Preferred Stock and Other Adjustments - (200) (100) -
Net Income Applicable to Common Shareholders (7,643) (5,584) (1,054) (2,531)